A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Completed · Phase 2

Conditions studied: Advanced Gastric Cancer

In brief

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

Key facts

Study ID

NCT02935634

Run by

Bristol-Myers Squibb

People needed

190

Starts

2016-11-29

Expected to finish

2022-05-11

Last updated by the study team

2023-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inoperable, advanced or metastatic esophageal cancer (EC), gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have histologically confirmed predominant adenocarcinoma and/or squamous carcinoma
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• At least 1 lesion with measurable disease

You may not qualify if…

• HER2-positive tumor and previously untreated with trastuzumab
• Suspected, known or progressive central nervous system metastases
• Other active malignancy requiring concurrent intervention
• Active, known or suspected autoimmune disease
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Mayo Clinic Arizona — Phoenix, Arizona, United States
• Local Institution - 0020 — Duarte, California, United States
• University Of Colorado — Aurora, Colorado, United States
• Local Institution - 0032 — New Haven, Connecticut, United States
• Local Institution - 0036 — Washington D.C., District of Columbia, United States
• UF Health Medical Oncology - Davis Cancer Pavilion — Gainesville, Florida, United States
• Local Institution - 0038 — Jacksonville, Florida, United States
• Local Institution - 0006 — Baltimore, Maryland, United States
• Local Institution - 0017 — Rochester, Minnesota, United States
• Local Institution - 0003 — St Louis, Missouri, United States
• Local Institution - 0001 — Hackensack, New Jersey, United States
• Local Institution - 0007 — New York, New York, United States
• Local Institution - 0002 — Portland, Oregon, United States
• Local Institution - 0005 — Philadelphia, Pennsylvania, United States
• UPMC — Pittsburgh, Pennsylvania, United States
• Local Institution - 0004 — Seattle, Washington, United States
• Local Institution - 0035 — Westmead, New South Wales, Australia
• Local Institution - 0033 — Heidelberg, Victoria, Australia
• Local Institution — Randwick, Australia
• Local Institution — Edmonton, Alberta, Canada
• Local Institution — Vancouver, British Columbia, Canada
• Local Institution — Ottawa, Ontario, Canada
• Local Institution - 0025 — Toronto, Ontario, Canada
• Local Institution - 0021 — Toronto, Ontario, Canada
• Local Institution - 0039 — Heidelberg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.